Terumo
4543.TPrecision Instruments
Financials · Standalone
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|---|
| Revenue | ¥452.2bn | ¥428.7bn | ¥399.8bn | ¥375.0bn | ¥341.4bn | ¥316.4bn |
| Operating income | ¥100.9bn | ¥89.4bn | ¥77.0bn | ¥67.8bn | ¥59.4bn | ¥51.9bn |
| Ordinary income | ¥174.5bn | ¥147.8bn | ¥110.7bn | ¥91.1bn | ¥79.4bn | ¥65.3bn |
| Total assets | ¥1.58T | ¥1.42T | ¥1.44T | ¥1.33T | ¥1.28T | ¥1.26T |
| Net assets / equity | ¥987.5bn | ¥870.0bn | ¥813.8bn | ¥765.6bn | ¥765.4bn | ¥725.2bn |
| EPS (basic) | ¥107.75 | ¥82.58 | ¥59.05 | ¥52.61r | ¥41.52r | ¥34.44r |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 14
| Period | Form | Figures |
|---|---|---|
| 2025-04-01 → 2026-03-31 | Annual | 216 figures · EDINET |
| 2025-04-01 → 2025-09-30 | Half-year | 86 figures · EDINET |
| 2024-04-01 → 2025-03-31 | Annual | 216 figures · EDINET |
| 2024-04-01 → 2024-09-30 | Half-year | 86 figures · EDINET |
| 2023-04-01 → 2024-03-31 | Annual | 216 figures · EDINET |
| 2023-04-01 → 2023-12-31 | Quarterly Q3 | 110 figures · EDINET |
| 2023-04-01 → 2023-09-30 | Quarterly Q2 | 110 figures · EDINET |
| 2023-04-01 → 2023-06-30 | Quarterly Q1 | 86 figures · EDINET |
| 2022-04-01 → 2023-03-31 | Annual | 216 figures · EDINET |
| 2022-04-01 → 2022-12-31 | Quarterly Q3 | 110 figures · EDINET |
| 2022-04-01 → 2022-09-30 | Quarterly Q2 | 110 figures · EDINET |
| 2022-04-01 → 2022-06-30 | Quarterly Q1 | 86 figures · EDINET |
| 2021-04-01 → 2022-03-31 | AnnualAmended | 231 figures · EDINET |
| 2021-04-01 → 2022-03-31 | Annual | 231 figures · EDINET |
25 more reports are still being processed.
Segments · FY ended 2026-03
| Segment | External sales | Profit |
|---|---|---|
| Blood And Cell Technologies Company | ¥231.0bn | ¥33.6bn |
| Cardiac And Vascular Company | ¥676.4bn | ¥164.0bn |
| Medical Care Solutions Company | ¥216.1bn | ¥21.6bn |
| Terumo Organ Technologies | ¥8.0bn | ¥1.7bn |
| Adjustments & eliminations | ¥294m | −¥1.5bn |
| Total | ¥1.13T | ¥220.9bn |
Segment names from EDINET member IDs; not mapped to a common taxonomy.